Bayesian adjusted R 2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials

Statistics in Medicine

Volumn 31, Issue 8, 2012, Pages 743-761

  Renfro, Lindsay A ^a   Shi, Qian ^a   Sargent, Daniel J ^a   Carlin, Bradley P ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bayesian mixed effects model; Bivariate survival; Clinical trials; Copula; Meta analysis; Surrogate endpoints

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; BIOLOGICAL MARKER;

ARTICLE; BAYES THEOREM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CLUSTER ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MATHEMATICAL MODEL; MAXIMUM LIKELIHOOD METHOD; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROCESS MODEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC ERROR; COLORECTAL TUMOR; COMPUTER SIMULATION; HUMAN; METHODOLOGY; STATISTICAL MODEL;

BAYES THEOREM; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL;

EID: 84858289836     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4416     Document Type: Article

References (21)

1. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989; 8:431-440. DOI: 10.1002/sim.4780080407.
2. Fleming TR. Surrogate markers in AIDS and cancer trials. Statistics in Medicine 1994; 13:1423-1435. DOI: 10.1002/sim.4780131318.
3. Hughes MD, De Gruttola V, Welles S. Evaluating surrogate markers. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995; 10:S1-S8.
4. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16:1965-1982. DOI: 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M.
5. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54:1014-1029. DOI: 10.2307/2533853.
6. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1:49-67. DOI: 10.1093/biostatistics/1.1.49.
7. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. Journal of the Royal Statistical Society, Series C (Applied Statistics) 2001; 50:405-422.
8. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, de Gramont AD. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials. Journal of Clinical Oncology 2005; 23:8664-8670. DOI: 10.1200/JCO.2005.01.6071.
9. Genest C, MacKay J. The joy of copulas: bivariate distributions with uniform marginals. The American Statistician 1986; 40:280-283. DOI: 10.2307/2684602.
10. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society, Series B (Methodological) 1972; 34:187-220.
11. Shih J, Louis T. Inferences on the association parameter in copula models for bivariate survival data. Biometrics 1995; 51:1384-1399. DOI: 10.2307/2533269.
12. Clayton DG. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 1978; 65:141-151. DOI: 10.1093/biomet/65.1.141.
13. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta analysis: multivariate approach and meta-regression. Statistics in Medicine 2002; 21:589-624. DOI: 10.1002/sim.1040.
14. Burzykowski T, Abrahantes JC. Validation in the case of two failure-time endpoints. In The Evaluation of Surrogate Endpoints, Burzykowski T, Molenberghs G, Buyse M (eds). Springer: New York, 2005; 163-194.
15. Tibaldi FS, Abrahantes JC, Molenberghs G, Renard D, Burzykowski T, Buyse M, Parmar M, Stijnen T, Wolfinger R. Simplified hierarchical linear models for the evaluation of surrogate endpoints. Journal of Statistical Computation and Simulation 2003; 73:643-658. DOI: 10.1080/0094965031000062177.
16. Shi Q, Renfro LA, Bot B, Burzykowski T, Buyse M, Sargent D. Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Computational Statistics and Data Analysis 2011; 55:2748-2757. DOI: 10.1016/j.csda.2011.03.0134.
17. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz J, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A. ACCENT Group. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20, 898 patients enrolled onto 18 randomized trials from the ACCENT group. Journal of Clinical Oncology 2007; 25:4569-4574. DOI: 10.1200/JCO.2006.10.4323.
18. Cowles MK. Evaluating surrogate endpoints for clinical trials: a Bayesian approach. Technical Report, Department of Statistics and Actuarial Science, University of Iowa, 2004.
19. Hotelling H. New light on the correlation coefficient and its transforms. Journal of the Royal Statistical Society, Series B 1953; 15:193-232.
20. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A. ACCENT Group. Two or three year disease free survival as a primary endpoint in stage III adjuvant colon cancer trials with fl{ligature}uoropyrimidines with or without oxaliplatin or irinotecan: data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803. European Journal of Cancer 2011; 47:990-996.
21. Burzykowski T. Surrogate endpoints: wishful thinking or reality? Statistical Methods in Medical Research 2008; 17:463-466. DOI: 10.1177/0962280207081866.